Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and Surgery

Summary by MedPage Today
(MedPage Today) -- The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity, said maker Novo Nordisk. The rate of...

1 Articles

MedPage TodayMedPage Today
Center

Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and Surgery

(MedPage Today) -- The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity, said maker Novo Nordisk. The rate of...

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States on Tuesday, May 6, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Wegovy icon

Wegovy

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal